ClinicalTrials.gg
Status unknownNCT01858415Updated Aug 13, 2013

Evaluation of Safety and Efficacy of TriPollar Device for Treatment of Wrinkles

An interventional study of TriPollar in Facial Wrinkles, sponsored by Pollogen. Status unknown at 2 sites in United States. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-13.

Sponsored by Pollogen (part of Lumenis Be Ltd.) · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2013), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
35 Years to 65 Years
Sex
All
01

Study summary

The TriPollar is intended for non invasive treatment of facial wrinkles and rhytides. This study was designed in order to evaluate the safety and efficacy of the TriPollar.

Read the detailed description

The TriPollar technology is based on three or more electrodes designed to deliver RF current focused into the skin, thus generating heat in the dermal layer. Selective and focused electro-heating of the skin is intended to stimulate collagen remodeling in the dermal layer resulting in non invasive wrinkle treatment.

02

Conditions studied

  • Facial Wrinkles
03

In context

Lead sponsor

Pollogen is the lead sponsor of 4 studies on the registry; none are open to participants now.

First submitted before Pollogen became part of Lumenis Be Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject read, discussed and signed the Consent Form,
  • Healthy female/male aged 35 65 years,
  • Has facial wrinkles,
  • Capable of reading, understanding and following instructions of the procedure to be applied,
  • Able and willing to comply with the treatment and follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  • Listed in approved protocol, and ICF
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Single arm

    Device: TriPollar

Interventions

  • DeviceTriPollar
06

What researchers measure

Primary outcomes

  1. Safety of TriPollar

    Safety will be established by physician's assessment/observation of adverse events.

    Time frame: 6 months

  2. Efficacy of TriPollar

    Efficacy will be established by level of wrinkle reduction at 3 m fu based on photos evaluation by independent physicians.

    Time frame: 6 months

07

Study locations

2 sites
  • Ronald L Moy, Inc.
    Beverly Hills, California 90210, United States
  • Reaserch Across America
    Plano, Texas 75093, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013 and a primary completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2013
First posted
May 21, 2013
Start
Apr 2013
Primary completionEst.
Dec 2013
Last update
Aug 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01858415
Lead sponsor
Pollogen
Responsible party
Sponsor
First posted
May 21, 2013
Start date
Apr 2013
Primary completion
Dec 2013 (estimated)
Last update
Aug 13, 2013

Study contacts

Mira Barki, PhD
study director · Pollogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion